Literature DB >> 26474317

MDS research criteria for prodromal Parkinson's disease.

Daniela Berg1, Ronald B Postuma2, Charles H Adler3, Bastiaan R Bloem4, Piu Chan5, Bruno Dubois6, Thomas Gasser1, Christopher G Goetz7, Glenda Halliday8, Lawrence Joseph9, Anthony E Lang10, Inga Liepelt-Scarfone1, Irene Litvan11, Kenneth Marek12, José Obeso13, Wolfgang Oertel14, C Warren Olanow15, Werner Poewe16, Matthew Stern17, Günther Deuschl18.   

Abstract

This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; diagnosis; prodromal

Mesh:

Year:  2015        PMID: 26474317     DOI: 10.1002/mds.26431

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  306 in total

Review 1.  Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism.

Authors:  Hong Jin; Jin-Ru Zhang; Yun Shen; Chun-Feng Liu
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 2.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

3.  Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies.

Authors:  Lucy Norcliffe-Kaufmann; Horacio Kaufmann; Jose-Alberto Palma; Cyndya A Shibao; Italo Biaggioni; Amanda C Peltier; Wolfgang Singer; Phillip A Low; David S Goldstein; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

Review 4.  Precision medicine for disease modification in Parkinson disease.

Authors:  Alberto J Espay; Patrik Brundin; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 5.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

Review 6.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

Review 7.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

8.  Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease.

Authors:  Jared T Hinkle; Kate Perepezko; Kelly A Mills; Zoltan Mari; Ankur Butala; Ted M Dawson; Alexander Pantelyat; Liana S Rosenthal; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2018-08-22       Impact factor: 4.891

9.  Effect of serum uric acid on cognition in patients with idiopathic REM sleep behavior disorder.

Authors:  Xudong Li; Shuhong Jia; Zhi Zhou; Yi Jin; Xiangfei Zhang; Chunlei Hou; Wenjing Zheng; Pei Rong; Jinsong Jiao
Journal:  J Neural Transm (Vienna)       Date:  2018-10-03       Impact factor: 3.575

10.  Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.

Authors:  Rui Liu; David M Umbach; Alexander I Tröster; Xuemei Huang; Honglei Chen
Journal:  Parkinsonism Relat Disord       Date:  2020-02-11       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.